免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据，仅供一般参考，不构成医疗建议、诊断、治疗建议或投资建议。

FDA 510(k)

Rejuvapen NXT

K号: K192138 · 2020-04-09

申请人Refine USA, LLC
决定日期2020-04-09
产品代码QAI
咨询委员会SU 请注意，您提供的文本“SU”不足以进行翻译。请提供完整的描述性文本以便进行翻译。
决定实质等同

器械摘要

Rejuvapen NXT is the device name listed in this FDA 510(k) record. The listed applicant is Refine USA, LLC. It received FDA 510(k) clearance on 2020-04-09 under 510(k) number K192138. The device is classified under product code QAI. It was reviewed by the SU advisory panel. FDA Decision: Substantially Equivalent.

常见问题

What is the Rejuvapen NXT?

Rejuvapen NXT is a medical device that received FDA 510(k) clearance on 2020-04-09. The listed applicant is Refine USA, LLC. The 510(k) number is K192138.

When did Rejuvapen NXT receive FDA 510(k) clearance?

Rejuvapen NXT received FDA 510(k) clearance on 2020-04-09, under 510(k) number K192138.

Who is the listed applicant for Rejuvapen NXT?

The FDA 510(k) record lists Refine USA, LLC as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Rejuvapen NXT?

The FDA product code for Rejuvapen NXT is QAI.

相关临床试验

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。

NCT07608549FLASHPilot 1期安全性研究NOT_YET_RECRUITINGNCT06562205PAP系统外部临床研究（ECS）NOT_YET_RECRUITINGNCT06443177交感神经调节对动脉瘤性蛛网膜下腔出血继发脑动脉痉挛的影响SUSPENDEDNCT07095751人工智能辅助尿路摄像头评估系统，用于诊断膀胱癌NOT_YET_RECRUITING

相关器械（代码：QAI）

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。

K252591自动微针系统（CODE-X）Woorhi Mechatronics Co., Ltd.K253002SkinStylus SteriLock MicroSystem (MP1209SL)Esthetic Medical, Inc.K252752艾拉科尔系统，配备微孔技术Cytrellis Biosystems, Inc.K253153SER Pen Carain 微系统 (MP1209SP)Su-Ko Technologies, LLCK243800PRO Pen微针治疗系统（6883）Dermalogica, LLCK243143E-PEN (E-PEN)Bomtech Electronics Co., Ltd.

官方来源

在 FDA 数据库中查看 →

数据来源于FDA开放API。如需最新且权威的信息，请务必参考官方记录。

↑